Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fernández-Díaz Carlos, Loricera Javier, Castañeda Santos, López-Mejías Raquel, Ojeda-García Clara, Olivé Alejandro, Rodríguez-Muguruza Samantha, Carreira Patricia E, Pérez-Sandoval Trinidad, Retuerto Miriam, Cervantes-Pérez Evelin C, Flores-Robles Bryan J, Hernández-Cruz Blanca, Urruticoechea Ana, Maíz-Alonso Olga, Arboleya Luis, Bonilla Gema, Hernández-Rodríguez Íñigo, Palma Desirée, Delgado Concepción, Expósito-Molinero Rosa, Ruibal-Escribano Ana, Álvarez-Rodríguez Belén, Blanco-Madrigal Juan, Bernal José A, Vela-Casasempere Paloma, Rodríguez-Gómez Manuel, Fito Concepción, Ortiz-Sanjuán Francisco, Narváez Javier, Moreno Manuel, López-Corbeto Mireia, Mena-Vázquez Natalia, Aguilera-Cros Clara, Romero-Yuste Susana, Ordóñez Sergi, Villa-Blanco Ignacio, Gonzélez-Vela M Carmen, Mora-Cuesta Víctor, Palmou-Fontana Natalia, Hernández José L, González-Gay Miguel A, Blanco Ricardo
Аннотация
METHODS: National multicenter, non-controlled, open-label registry study of RA patients with ILD treated with ABA.
RESULTS: 63 patients (36 women) with RA-associated ILD undergoing ABA therapy were studied. The mean ± standard deviation age at the time of the study was 63.2 ± 9.8 years. The median duration of RA and ILD from diagnosis were 6.8 and 1 year, respectively. RA was seropositive in 55 patients (87.3%). In 15 (23.8%) of 63 patients the development of ILD was closely related to the administration of synthetic or biologic disease modifying anti-rheumatic drugs. After a follow-up of 9.4 ± 3.2 months, two-thirds of patients remained stable whereas one-quarter experienced improvement in the Modified Medical Research Council scale. At that time forced vital capacity remained stable in almost two-thirds of patents and improved in one out of five patients assessed. Also, diffusing capacity of the lung for carbon monoxide remained stable in almost two-thirds and showed improvement in a quarter of the patients assessed. At 12 months, 50% of the 22 patients in whom chest HRCT scan was performed due persistence of respiratory symptoms showed stabilization, 8 (36.4%) improvement and 3 worsening of the HRCT scan pattern. Eleven of 63 patients had to discontinue ABA, mainly due to adverse events.
CONCLUSION: ABA appears to be an effective in RA-associated ILD.